GRAIL, Inc.

GRAL Healthcare Diagnostics & Research

GRAIL, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $147.2 million, up 17.2% from fiscal 2024.

Revenue
+3.71%
EPS
+10.2%
Free cash flow
−24.9%

Quarter to September 2026, against a year earlier

124.40 19.26 −13.41%
Market cap
$5.3B
P/E
0.0×
Fwd P/E
−14.5×
Dividend yield
—
F-score
6/9
Altman Z
0.37
Beneish M
n/a
Dividend safety
n/a

GRAIL, Inc. (GRAL) P/B ratio

Alert me on P/B ratio

As of 5 November 2026, GRAIL, Inc. (GRAL) trades at a P/B ratio of 2.4×. Over the past ten years it has ranged from 0.1× (June 2024) to 3.0× (October 2026); the current reading is higher than 96% of that period. That is below the Diagnostics & Research industry median of 3.4× and in line with the Healthcare sector median of 2.3×.

P/B ratio, daily

Embed this chart

Annual newest first

Period P/B ratio Change
FY2025 1.2× 436.40%
FY2024 0.2× 95.61%
FY2023 0.1× 0.00%
FY2022 0.1× —

Quarterly newest first

Period P/B ratio Change
Sep 2026 2.7× 130.78%
Jun 2026 1.2× 37.83%
Mar 2026 0.8× (31.17%)
Dec 2025 1.2× 27.97%
9 more quarters

Against its own ten years

Low 0.1× High 3.0×
Ten-year median 0.6×
Current reading's percentile 96

P/B ratio against peers

Company P/B ratio
VCYT Veracyte, Inc. compare 1.4×
ICLR ICON PLC compare 1.7×
GRAL GRAIL, Inc. 2.4×
QGEN QIAGEN N.V. compare 3.1×
RDNT RadNet, Inc. compare 4.4×
SHC Sotera Health Company compare 6.2×
CDNA CareDx, Inc. compare 8.6×
BLLN BillionToOne, Inc. compare 9.9×
ADPT Adaptive Biotechnologies Corporation compare 23.5×
Diagnostics & Research industry median 3.4×
Healthcare sector median 2.3×
Market median 1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

More on GRAL